Clinical Features of Hepatitis D

 

 Permissions and Reprints

Abstract

Hepatitis D is caused by infection with hepatitis D virus (HDV), a defective RNA virus that requires the obligatory helper function of hepatitis B virus (HBV) for its in vivo transmission. Thus, HDV is acquired only by coinfection with HBV or by superinfection of an HBV carrier. The clinical outcome of hepatitis D differs according to the modality of infection. Whereas coinfection evolves to chronicity in only 2% of the cases, superinfection results in chronic infection in over 90% of the cases. HDV is a highly pathogenic virus that causes acute, often fulminant hepatitis, as well as a rapidly progressive form of chronic viral hepatitis, leading to cirrhosis in 70 to 80% of the cases. The clinical picture of HDV disease is evolving as a consequence of a significant change in the epidemiology of HDV infection, which has led to a significant decline in incidence in Western countries, mainly as a result of universal HBV vaccination programs. However, in the face of a declining prevalence in areas of old endemicity like Europe, immigration poses a threat of HDV resurgence. The interaction of HDV with other hepatitis viruses or human immunodeficiency virus is complex and may lead to different patterns in terms of virologic expression and immunologic responses. Multiple viral infections are associated with rapid progression of liver fibrosis and eventually with the development of hepatocellular carcinoma. Hepatitis D is not a vanishing disease, and continuous efforts should be made to improve its prevention and treatment.

• References

• 1 Rizzetto M, Canese MG, Aricò S , et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977; 18 (12) 997-1003
  CrossrefPubMedGoogle Scholar
• 2 Rizzetto M, Canese MG, Gerin JL, London WT, Sly DL, Purcell RH. Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis 1980; 141 (5) 590-602
  CrossrefPubMedGoogle Scholar
• 3 Rizzetto M, Smedile A. Hepatitis D. In: Schiff ER, Sorrell M, Maddrey W, , eds. Diseases of the Liver. Philadelphia, PA: Lippincott, Williams and Wilkins; 2002: 863-875
  Google Scholar
• 4 Farci P. Delta hepatitis: an update. J Hepatol 2003; 39 (Suppl. 01) S212-S219
  CrossrefPubMedGoogle Scholar
• 5 Taylor J, Farci P, Purcell RH. Hepatitis D (Delta) virus. In: Knipe DM, Howley PM, , eds. Field's Virology. 5th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2006: 3031-3046
  Google Scholar
• 6 Purcell RH, Satterfield WC, Bergmann KF, Smedile A, Ponzetto A, Gerin JL. Experimental hepatitis delta virus infection in the chimpanzee. Prog Clin Biol Res 1987; 234: 27-36
  PubMedGoogle Scholar
• 7 Caredda F, Rossi E, d'Arminio Monforte A , et al. Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome. J Infect Dis 1985; 151 (5) 925-928
  CrossrefPubMedGoogle Scholar
• 8 Smedile A, Farci P, Verme G , et al. Influence of delta infection on severity of hepatitis B. Lancet 1982; 2 (8305) 945-947
  PubMedGoogle Scholar
• 9 Smedile A, Ciancio A, Rizzetto M. Hepatitis D. In: Richmann DD, Whitley RJ, Hayden FG, , eds. Clinical Virology: Hepatitis Delta Virus. Washington, DC: ASM Press; 2002: 1227-1240
  Google Scholar
• 10 Raimondo G, Longo G, Squadrito G. Exacerbation of chronic liver disease due to hepatitis B surface antigen after delta infection. Br Med J (Clin Res Ed) 1983; 286 (6368) 845
  PubMedGoogle Scholar
• 11 Farci P, Smedile A, Lavarini C , et al. Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating acute hepatitis B progressive to chronicity. Gastroenterology 1983; 85 (3) 669-673
  PubMedGoogle Scholar
• 12 Smedile A, Dentico P, Zanetti A , et al. Infection with the delta agent in chronic HBsAg carriers. Gastroenterology 1981; 81 (6) 992-997
  PubMedGoogle Scholar
• 13 Niro GA, Gravinese E, Martini E , et al. Clearance of hepatitis B surface antigen in chronic carriers of hepatitis delta antibodies. Liver 2001; 21 (4) 254-259
  PubMedGoogle Scholar
• 14 Ottobrelli A, Marzano A, Smedile A , et al. Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology 1991; 101 (6) 1649-1655
  PubMedGoogle Scholar
• 15 Smedile A, Casey JL, Cote PJ , et al. Hepatitis D viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope. Hepatology 1998; 27 (6) 1723-1729
  CrossrefPubMedGoogle Scholar
• 16 Lee WM. Acute liver failure. N Engl J Med 1993; 329 (25) 1862-1872
  CrossrefPubMedGoogle Scholar
• 17 Trey C. The fulminant hepatic failure surveillance study. Brief review of the effects of presumed etiology and age of survival. Can Med Assoc J 1972; 106: 525-528
  PubMedGoogle Scholar
• 18 Saracco G, Macagno S, Rosina F, Rizzetto M. Serologic markers with fulminant hepatitis in persons positive for hepatitis B surface antigen. A worldwide epidemiologic and clinical survey. Ann Intern Med 1988; 108 (3) 380-383
  CrossrefPubMedGoogle Scholar
• 19 Rizzetto M, Verme G, Recchia S , et al. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 1983; 98 (4) 437-441
  CrossrefPubMedGoogle Scholar
• 20 Saracco G, Rosina F, Brunetto MR , et al. Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. J Hepatol 1987; 5 (3) 274-281
  CrossrefPubMedGoogle Scholar
• 21 Fattovich G, Giustina G, Christensen E , et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000; 46 (3) 420-426
  CrossrefPubMedGoogle Scholar
• 22 Rosina F, Conoscitore P, Cuppone R , et al. Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology 1999; 117 (1) 161-166
  CrossrefPubMedGoogle Scholar
• 23 Verme G, Brunetto MR, Oliveri F , et al. Role of hepatitis delta virus infection in hepatocellular carcinoma. Dig Dis Sci 1991; 36 (8) 1134-1136
  CrossrefPubMedGoogle Scholar
• 24 Romeo R, Del Ninno E, Rumi M , et al. A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009; 136 (5) 1629-1638
  CrossrefPubMedGoogle Scholar
• 25 Niro GA, Smedile A, Ippolito AM , et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol 2010; 53 (5) 834-840
  CrossrefPubMedGoogle Scholar
• 26 Cross TJ, Rizzi P, Horner M , et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol 2008; 80 (2) 277-282
  CrossrefPubMedGoogle Scholar
• 27 Buti M, Homs M, Rodriguez-Frias F , et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat 2011; 18 (6) 434-442
  CrossrefPubMedGoogle Scholar
• 28 Sakugawa H, Nakasone H, Nakayoshi T , et al. Hepatitis B virus concentrations in serum determined by sensitive quantitative assays in patients with established chronic hepatitis delta virus infection. J Med Virol 2001; 65 (3) 478-484
  CrossrefPubMedGoogle Scholar
• 29 Zachou K, Yurdaydin C, Drebber U , et al; HIDT-1 Study Group. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int 2010; 30 (3) 430-437
  CrossrefPubMedGoogle Scholar
• 30 Farci P, Gerin JL, Aragona M , et al. Diagnostic and prognostic significance of the IgM antibody to the hepatitis delta virus. JAMA 1986; 255 (11) 1443-1446
  CrossrefPubMedGoogle Scholar
• 31 Borghesio E, Rosina F, Smedile A , et al. Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation. Hepatology 1998; 27 (3) 873-876
  CrossrefPubMedGoogle Scholar
• 32 Crivelli O, Lavarini C, Chiaberge E , et al. Microsomal autoantibodies in chronic infection with the HBsAg associated delta (delta) agent. Clin Exp Immunol 1983; 54 (1) 232-238
  PubMedGoogle Scholar
• 33 Philipp T, Durazzo M, Trautwein C , et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet 1994; 344 (8922) 578-581
  CrossrefPubMedGoogle Scholar
• 34 Lavarini C, Caredda F, Ballarè M , et al. Development of tissue antibodies in hepatitis delta virus infection. In: Zuckermann AJ, , ed. Viral Hepatitis and Liver Disease. New York: Liss; 1988: 439-441
  Google Scholar
• 35 Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 1991; 13 (6) 1052-1056
  CrossrefPubMedGoogle Scholar
• 36 Verme G, Amoroso P, Lettieri G , et al. A histological study of hepatitis delta virus liver disease. Hepatology 1986; 6 (6) 1303-1307
  CrossrefPubMedGoogle Scholar
• 37 Govindarajan S, de Cock KM, Peters RL. Morphologic and immunohistochemical features of fulminant delta hepatitis. Hum Pathol 1985; 16 (3) 262-267
  CrossrefPubMedGoogle Scholar
• 38 Popper H, Thung SN, Gerber MA , et al. Histologic studies of severe delta agent infection in Venezuelan Indians. Hepatology 1983; 3 (6) 906-912
  PubMedGoogle Scholar
• 39 Deny P. Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades. In: Casey JL, , ed. Hepatitis Delta Virus. Heidelberg, Germany: Springer; 2006: 151 171;
  CrossrefGoogle Scholar
• 40 Niro GA, Smedile A, Andriulli A, Rizzetto M, Gerin JL, Casey JL. The predominance of hepatitis delta virus genotype I among chronically infected Italian patients. Hepatology 1997; 25 (3) 728-734
  CrossrefPubMedGoogle Scholar
• 41 Wu JC. Functional and clinical significance of hepatitis D virus genotype II infection. Curr Top Microbiol Immunol 2006; 307: 173-186
  PubMedGoogle Scholar
• 42 Su CW, Huang YH, Huo TI , et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 2006; 130 (6) 1625-1635
  CrossrefPubMedGoogle Scholar
• 43 Casey JL, Brown TL, Colan EJ, Wignall FS, Gerin JL. A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci U S A 1993; 90 (19) 9016-9020
  CrossrefPubMedGoogle Scholar
• 44 Manock SR, Kelley PM, Hyams KC , et al. An outbreak of fulminant hepatitis delta in the Waorani, an indigenous people of the Amazon basin of Ecuador. Am J Trop Med Hyg 2000; 63 (3-4) 209-213
  PubMedGoogle Scholar
• 45 Gomes-Gouvêa MS, Soares MC, Bensabath G , et al. Hepatitis B virus and hepatitis delta virus genotypes in outbreaks of fulminant hepatitis (Labrea black fever) in the western Brazilian Amazon region. J Gen Virol 2009; 90 (Pt 11) 2638-2643
  CrossrefPubMedGoogle Scholar
• 46 Radjef N, Gordien E, Ivaniushina V , et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol 2004; 78 (5) 2537-2544
  CrossrefPubMedGoogle Scholar
• 47 Gaeta GB, Stroffolini T, Chiaramonte M , et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology 2000; 32 (4 Pt 1) 824-827
  CrossrefPubMedGoogle Scholar
• 48 Rizzetto M. Hepatitis D: thirty years after. J Hepatol 2009; 50 (5) 1043-1050
  CrossrefPubMedGoogle Scholar
• 49 Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection—not a vanishing disease in Europe!. Hepatology 2007; 45 (5) 1331-1332 , author reply 1332–1333
  PubMedGoogle Scholar
• 50 Gaeta GB, Stroffolini T, Smedile A, Niro G, Mele A. Hepatitis delta in Europe: vanishing or refreshing?. Hepatology 2007; 46 (4) 1312-1313
  PubMedGoogle Scholar
• 51 Erhardt A, Knuth R, Sagir A, Kirschberg O, Heintges T, Häussinger D. Socioepidemiological data on hepatitis delta in a German university clinic—increase in patients from Eastern Europe and the former Soviet Union. Z Gastroenterol 2003; 41 (6) 523-526
  Article in Thieme ConnectPubMedGoogle Scholar
• 52 Yurdaydin C. Delta hepatitis in Turkey: decreasing but not vanishing and still of concern. Turk J Gastroenterol 2006; 17 (1) 74-75
  PubMedGoogle Scholar
• 53 Crockett SD, Keeffe EB. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob 2005; 4: 13
  CrossrefPubMedGoogle Scholar
• 54 Ganesh Kumar A, Sridharan K, Thirunalasundari T. Prevalence pattern of blood borne hepatitis group of viruses in liver disease patients. World Med Sci 2007; 2: 33-38
  PubMedGoogle Scholar
• 55 Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 2003; 38 (1) 4-13
  PubMedGoogle Scholar
• 56 Riaz M, Idrees M, Kanwal H, Kabir F. An overview of triple infection with hepatitis B, C and D viruses. Virol J 2011; 8: 368
  CrossrefPubMedGoogle Scholar
• 57 Liaw Y-F, Tsai S-L, Sheen I-S , et al. Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers. Am J Gastroenterol 1998; 93 (3) 354-359
  CrossrefPubMedGoogle Scholar
• 58 Wu JC, Chen CL, Hou MC, Chen TZ, Lee SD, Lo KJ. Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: application and limitations of the polymerase chain reaction. Hepatology 1994; 19 (4) 836-840
  CrossrefPubMedGoogle Scholar
• 59 Sagnelli E, Coppola N, Scolastico C , et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000; 32 (5) 1106-1110
  CrossrefPubMedGoogle Scholar
• 60 Mathurin P, Thibault V, Kadidja K , et al. Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. J Viral Hepat 2000; 7 (1) 15-22
  PubMedGoogle Scholar
• 61 Jardi R, Rodriguez F, Buti M , et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001; 34 (2) 404-410
  CrossrefPubMedGoogle Scholar
• 62 Raimondo G, Brunetto MR, Pontisso P , et al; Associazione Italiana Studio Fegato Cooperative Group. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 2006; 43 (1) 100-107
  CrossrefPubMedGoogle Scholar
• 63 Colombari R, Dhillon AP, Piazzola E , et al. Chronic hepatitis in multiple virus infection: histopathological evaluation. Histopathology 1993; 22 (4) 319-325
  CrossrefPubMedGoogle Scholar
• 64 Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127 (5, Suppl 1) S35-S50
  CrossrefPubMedGoogle Scholar
• 65 Oyunsuren T, Kurbanov F, Tanaka Y , et al. High frequency of hepatocellular carcinoma in Mongolia; association with mono-, or co-infection with hepatitis C, B, and delta viruses. J Med Virol 2006; 78 (12) 1688-1695
  CrossrefPubMedGoogle Scholar
• 66 Tsatsralt-Od B, Takahashi M, Nishizawa T, Endo K, Inoue J, Okamoto H. High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia. J Med Virol 2005; 77 (4) 491-499
  CrossrefPubMedGoogle Scholar
• 67 Khan A, Kurbanov F, Tanaka Y , et al. Epidemiological and clinical evaluation of hepatitis B, hepatitis C, and delta hepatitis viruses in Tajikistan. J Med Virol 2008; 80 (2) 268-276
  CrossrefPubMedGoogle Scholar
• 68 Pontisso P, Ruvoletto MG, Fattovich G , et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993; 105 (5) 1529-1533
  CrossrefPubMedGoogle Scholar
• 69 Modahl LE, Lai MM. The large delta antigen of hepatitis delta virus potently inhibits genomic but not antigenomic RNA synthesis: a mechanism enabling initiation of viral replication. J Virol 2000; 74 (16) 7375-7380
  CrossrefPubMedGoogle Scholar
• 70 Deterding K, Pothakamuri SV, Schlaphoff V , et al. Clearance of chronic HCV infection during acute delta hepatitis. Infection 2009; 37 (2) 159-162
  CrossrefPubMedGoogle Scholar
• 71 Benhamou Y, Bochet M, Di Martino V , et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-1058
  CrossrefPubMedGoogle Scholar
• 72 Puoti M, Bonacini M, Spinetti A , et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001; 183: 134-137
  CrossrefPubMedGoogle Scholar
• 73 Gaeta GB, Precone DF, Cozzi-Lepri A, Cicconi P, D'Arminio Monforte A. Multiple viral infections. J Hepatol 2006; 44 (1, Suppl) S108-S113
  PubMedGoogle Scholar
• 74 Arribas JR, González-García JJ, Lorenzo A , et al. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain. AIDS 2005; 19 (13) 1361-1365
  CrossrefPubMedGoogle Scholar
• 75 Boyd A, Lacombe K, Miailhes P , et al. Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. J Viral Hepat 2010; 17 (1) 65-76
  CrossrefPubMedGoogle Scholar
• 76 Pol S, Wesenfelder L, Dubois F , et al. Influence of human immunodeficiency virus infection on hepatitis delta virus superinfection in chronic HBsAg carriers. J Viral Hepat 1994; 1 (2) 131-137
  CrossrefPubMedGoogle Scholar
• 77 Schaper M, Rodriguez-Frias F, Jardi R , et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol 2010; 52 (5) 658-664
  CrossrefPubMedGoogle Scholar
• 78 Soriano V, Grint D, d'Arminio Monforte A , et al. Hepatitis delta in HIV-infected individuals in Europe. AIDS 2011; 25 (16) 1987-1992
  CrossrefPubMedGoogle Scholar
• 79 Castellares C, Barreiro P, Martín-Carbonero L , et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat 2008; 15 (3) 165-172
  PubMedGoogle Scholar
• 80 Rizzetto M. Delta hepatitis: Forgotten, but not gone. Curr Hepatitis Rep 2010; 9: 239-242
  CrossrefPubMedGoogle Scholar